Search
Search
William F. Wiley, MD
Show Description +
With an increasing number of premium IOL options available, William F. Wiley, MD, describes how the RxLAL (RxSight) technology fits into today's practice. About 92% of patients enrolled in the FDA trials of the RxLAL were within ±0.50 D of intended target, he says. In this new era of technology, Dr. Wiley classifies patients depending on their lifestyle goals and then selects the IOL based on those goals.
Posted: 2/10/2020
William F. Wiley, MD
With an increasing number of premium IOL options available, William F. Wiley, MD, describes how the RxLAL (RxSight) technology fits into today's practice. About 92% of patients enrolled in the FDA trials of the RxLAL were within ±0.50 D of intended target, he says. In this new era of technology, Dr. Wiley classifies patients depending on their lifestyle goals and then selects the IOL based on those goals.
Posted: 2/10/2020
Please log in to leave a comment.